Viewing nowCombinationLobartan Tablet 10/80 mg
Rosuvastatin Calcium 10.4mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.

MFDS item code 202003858 · Approved 2020.05.26 · Insurance code 646005080
Treatment of hypertension and heart failure, improvement of dyslipidemia, reduction of the risk of atherosclerosis and cardiovascular disease
This medication is specifically used for patients who need to take both valsartan and rosuvastatin. Valsartan primarily helps to reduce the risk of death that may occur after essential hypertension, heart failure, and myocardial infarction. It is particularly effective for heart failure patients who cannot use ACE inhibitors. Meanwhile, rosuvastatin assists patients with hypercholesterolemia and mixed dyslipidemia when diet and exercise alone are not sufficient, playing an important role in reducing cardiovascular disease risk. It is also used as an adjunct to diet in cases of homozygous familial hypercholesterolemia. These two medications manage blood pressure and improve blood lipids simultaneously, effectively enhancing cardiovascular health.
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, valsartan/rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The antihypertensive effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily, or a diuretic may be coadministered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily, and may be increased to 80 mg or 160 mg per dose. When coadministered with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, followed by dose titration over several weeks, taking patient tolerability into consideration, to 40 mg, 80 mg, and 160 mg per dose twice daily. Dose reduction should be considered if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary if creatinine clearance is 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; the dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus if taken during pregnancy, particularly in the second and third trimesters; therefore, it should be discontinued immediately upon confirmation of pregnancy. Pregnant women or women who may become pregnant, nursing mothers, and patients allergic to any ingredients in this medication should not take it. Patients with severe liver function impairment, very poor kidney function, or certain muscle diseases should also avoid this medication. Elderly patients, patients with high potassium levels, patients with slightly impaired liver function, and those with cardiovascular disease should use this medication cautiously. This medication can cause muscle pain, muscle weakness, and, rarely, severe muscle breakdown, so any muscle-related symptoms should be discussed immediately with a doctor. While taking this medication, blood tests for liver function and regular blood tests should be performed, and patients at risk for liver disease or diabetes should use it with greater caution. Drug interactions may occur when taken with other medications, so it is essential to inform the doctor or pharmacist of any other drugs being taken. This medication has not been established for safety and efficacy in children and adolescents. In case of overdose, there is no specific antidote; therefore, immediate medical attention should be sought for appropriate treatment. This medication should be stored out of the reach of children and should not be transferred to other containers.
Indigestion, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial swelling, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum hepatic aminotransferase levels, increased serum creatine phosphokinase, increased serum potassium, increased gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, hypersensitivity, anxiety, upper respiratory tract infection, pharyngitis, tonsillitis, spinal canal stenosis, aphasia, oral hemorrhage, vomiting, insulin-dependent diabetes mellitus, diabetes complications, leg fractures, spinal fractures, fractures, skin mass, second-degree atrioventricular block, vestibular neuritis, retinal detachment, unspecified skin tumor-like condition, herpes zoster, intervertebral disc herniation, hemoptysis, cough disorders, bronchitis, sensory disturbances, hoarseness, gastroesophageal reflux, diverticulitis, stomatitis, gastritis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, increased triglycerides, elevated blood pressure, worsening hypertension, neck/shoulder pain, toe fractures, osteomyelitis, skin infections, unspecified dermatitis, localized skin reaction, palpitations, aggravated angina, auditory disturbances, overactive bladder, increased serum creatinine, benign prostatic hyperplasia, lacerated wound, headache, dizziness, constipation, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, peripheral neuropathy, memory loss, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, eosinophilia with systemic symptoms drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory decline, forgetfulness, amnesia, memory impairment, confusion, severe muscle weakness, ocular myasthenia, hypotension, decreased consciousness, circulatory collapse, shock, tachycardia, bradycardia, hypoglycemia, angioedema, interstitial pneumonia, syncope, vascular angioedema, renal impairment, hematological adverse reactions, hyperkalemia, shock, hypotension, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, decreased red blood cell volume, decreased hemoglobin, viral infection, upper respiratory tract infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain, abdominal pain, arthralgia, hypotension, orthostasis dizziness, orthostatic hypotension, renal impairment, angioedema, erythema, pruritus, serum sickness, vasculitis, hepatitis, arrhythmia, intestinal vascular edema, interstitial pneumonia, hypoglycemia, angioedema, hepatitis, renal failure, shock, syncope, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, decreased red blood cell volume, decreased hemoglobin, edema
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container that can block light and should ideally be kept at room temperature between 1 to 30 degrees Celsius. Storing it this way will help maintain the medication's effectiveness for a long time.
Pink round film-coated tablet
30 tablets/box [(10 tablets/PTP)*3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationRosuvastatin Calcium 10.4mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Rosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Medika Korea Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.